MSDx, Inc. (MSDx) provides novel biomarker tools for studying disease processes. The company is focused on commercializing both Research Use Only (RUO) and In Vitro Diagnostic (IVD) blood test products that will be used in monitoring neurological, autoimmune, and inflammatory disorders. The company initially discovered a novel source of biomarkers that reflect the disease activity of a multiple sclerosis (MS) patient. These biomarkers may provide meaningful information that can aid in monitoring disease progression and response to drug therapy, predict an impending relapse, and facilitate drug development. Ultimately healthcare costs can be reduced if disease progression is slowed by getting patients aligned with the optimal medication.